title: Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene.
abstract: We constructed recombinant vaccinia viruses (RVVs) that expressed human T-cell leukemia virus type I (HTLV-I) envelope glycoproteins by using attenuated vaccinia viruses (VVs) which have much lower neurovirulence than the WR strain that is extensively used as a vector. The RVV produced from the LC16mO strain, one of the attenuated VVs, elicited a high titer of anti-HTLV-I antibody in rabbits and protected them against HTLV-I infection. The env gene was inserted into the VV hemagglutinin gene. The resultant inactivation of the hemagglutinin gene led to the attenuation of VVs, but the extent of their attenuation depended on the VV strain. The propagation of LC16mO and its RVV in rabbit brain was poorer than that of LO-1, a cloned derivative of Lister strain, and its RVV, although LC16mO replicated in other organs better than did LO-1. Taken together, these results suggest that LC16mO is a good candidate as a vector for vaccination of humans.
authors.affiliation: Institute for Virus Research, Kyoto University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Shida
authors.forename: Y
authors.initials: Y
authors.lastname: Hinuma
authors.forename: M
authors.initials: M
authors.lastname: Hatanaka
authors.forename: M
authors.initials: M
authors.lastname: Morita
authors.forename: M
authors.initials: M
authors.lastname: Kidokoro
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Maruyama
authors.forename: F
authors.initials: F
authors.lastname: Takahashi-Nishimaki
authors.forename: M
authors.initials: M
authors.lastname: Sugimoto
authors.forename: R
authors.initials: R
authors.lastname: Kitamura
mesh_terms: D000818:Animals; D001921:Brain / Q000382:microbiology; D002460:Cell Line; D005786:Gene Expression Regulation; D005814:Genes, Viral; D006023:Glycoproteins / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D015490:HTLV-I Infections / Q000517:prevention & control; D006389:Hemagglutinins, Viral / Q000235:genetics; D015368:Human T-lymphotropic virus 1 / Q000235:genetics* / Q000276:immunology; D008297:Male; D051379:Mice; D011233:Precipitin Tests; D011817:Rabbits; D014612:Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics* / Q000254:growth & development / Q000276:immunology / Q000472:pathogenicity; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines; D014774:Virulence
chemical_list: D006023:Glycoproteins; D006389:Hemagglutinins, Viral; D014612:Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines